A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight
Key facts
- Where
- Berlin, Bochum, Bünde, Dresden, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Hamburg, Hanover, Homburg, Jerichow, Karlsruhe, Leipzig, Magdeburg, Mainz, München, Offenbach Am Main és Schwerin, NémetországSee the 22 sites
- Phase
- 3. fázis
Where in Németország
- FutureMeds GmbHBerlin, NémetországTaking people
- Klinische Forschung Berlin-Mitte GmbHBerlin, NémetországTaking people
- Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbHBochum, NémetországTaking people
- Internistische GemeinschaftspraxisBünde, NémetországTaking people
- Klinische Forschung Dresden GmbHDresden, NémetországTaking people
- ClinPhenomics CVC GmbHFrankfurt am Main, NémetországTaking people
- IKF Pneumologie GmbH & Co. KGFrankfurt am Main, NémetországTaking people
- Universitaetsklinikum Frankfurt AöRFrankfurt Am Main, NémetországTaking people
- Medical Center- University of FreiburgFreiburg im Breisgau, NémetországTaking people
- Universitaetsmedizin GoettingenGoettingen, NémetországTaking people
- Klinische Forschung Hamburg GmbHHamburg, NémetországTaking people
- Velocity Clinical Research Germany GmbHHamburg, NémetországTaking people
- Klinische Forschung Hannover-Mitte GmbHHanover, NémetországTaking people
- Universitaetsklinikum des Saarlandes AöRHomburg, NémetországTaking people
- Praxisgemeinschaft JerichowJerichow, NémetországTaking people
- Klinische Forschung Karlsruhe GmbHKarlsruhe, NémetországTaking people
- Velocity Clinical Research Germany GmbHLeipzig, NémetországTaking people
- Institut Fuer Praeventive Medizin & Klinische Forschung GbRMagdeburg, NémetországTaking people
- IKF Pneumologie GmbH & Co. KGMainz, NémetországTaking people
- Hausarztpraxis am HeimeranplatzMünchen, NémetországTaking people
- FutureMeds GmbHOffenbach Am Main, NémetországTaking people
- Klinische Forschung Schwerin GmbHSchwerin, NémetországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca AB
- Trial code
- EU 2025-524616-11-00
- Record updated
- 2026. október 9.
- Original description
To evaluate the effect of AZD6234 as compared to placebo in percent body weight change from baseline at 68 weeks of treatmentRead full original descriptionShow less
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight
To evaluate the effect of AZD6234 as compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Inclusion: Males & females ≥ 18 years of age; BMI ≥ 27 kg/m2; Diagnosed with T2DM ≥ 90 days prior to Screening; HbA1c value at Screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling); Stable body weight (≤ 5% body weight change) for at least 3 months prior to Randomisation; History of at least one self-reported unsuccessful attempt to lose body weight in lifetime.
Exclusion: Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening; Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation; Use of insulin therapy for T2DM within 3 months prior to screening; Obesity primarily caused by other endocrine disorders; Significant hepatobiliary disease and/or any of the following results at Screening: - ALT ≥ 3.0 X ULN - AST ≥ 3.0 X ULN - TBL > 1.5 X ULN (except for cases of known Gilbert’s Syndrome).